Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Phase 2 Completed 9 enrolled Vanderbilt-Ingram Cancer Center National Cancer Institute (NCI) · collab National Comprehensive Cancer Network · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2015-01
Primary completion: 2018-08
Completion: 2021-04-16

Publications

Nebhan CA, Johnson DB, Sullivan RJ, Amaria RN, Flaherty KT, Sosman JA, Davies MA. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. Oncologist. 2021 Sep;26(9):731-e1498. doi: 10.1002/onco.13795. Epub 2021 May 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Trametinib	Small molecule	2 mg	Oral

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Summary

Timeline

Publications

Drugs

Indications